Gary Gize, MD | Authors

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

February 01, 2001

A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing